We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -20.00 | -0.16% | 12,106.00 | 12,120.00 | 12,122.00 | 12,190.00 | 12,024.00 | 12,080.00 | 999,558 | 16:35:02 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.55 | 187.98B |
Hot Features
Premium
RNS Number:5460K
AstraZeneca PLC
30 April 2003
Consolidated Profit & Loss Account
For the quarter ended 31 March 2003 2002
$m $m
Sales 4,735 4,346
Cost of sales (1,135) (1,094)
Distribution costs (35) (30)
Research and development (782) (697)
Selling, general and administrative expenses (1,526) (1,384)
Other operating income 15 156
Operating profit 1,272 1,297
Net interest and dividend income 21 21
Profit on ordinary activities before taxation 1,293 1,318
Taxation (356) (356)
Profit on ordinary activities after taxation 937 962
Attributable to minorities (5) (4)
Net profit for the period 932 958
Earnings per Ordinary Share before exceptional items $0.54 $0.55
Earnings per Ordinary Share $0.54 $0.55
Diluted earnings per Ordinary Share $0.54 $0.55
Weighted average number of Ordinary Shares in issue (millions) 1,717 1,745
Diluted average number of Ordinary Shares in issue (millions) 1,718 1,747
Consolidated Balance Sheet
At 31 March 2003 2002
$m $m
Fixed assets 9,566 8,205
Current assets 12,929 11,754
Total assets 22,495 19,959
Creditors due within one year (8,146) (7,220)
Net current assets 4,783 4,534
Total assets less current liabilities 14,349 12,739
Creditors due after more than one year (363) (788)
Provisions for liabilities and charges (1,832) (1,473)
Net assets 12,154 10,478
Capital and reserves
Shareholders' funds and minority interests 12,154 10,478
Consolidated Cash Flow Statement
For the quarter ended 31 March 2003 2002
$m $m
Cash flow from operating activities
Operating profit 1,272 1,297
Depreciation and amortisation 272 227
(Increase)/decrease in working capital and other non-cash movements (370) 409
Net cash inflow from operating activities before exceptional items 1,174 1,933
Outflow related to exceptional items (12) (28)
Net cash inflow from operating activities 1,162 1,905
Returns on investments and servicing of finance (9) (6)
Tax paid (252) (54)
Capital expenditure and financial investment (330) (285)
Net cash inflow before management of liquid resources
and financing 571 1,560
Net purchase of shares (129) (133)
Exchange and other movements 13 (2)
Increase in net cash funds in the period 455 1,425
Net cash funds at beginning of period 3,844 2,867
Net cash funds at end of period 4,299 4,292
Notes to the Interim Financial Statements
1 BASIS OF PREPARATION AND ACCOUNTING POLICIES
The results for the quarter ended 31 March 2003 have been prepared in accordance
with UK generally accepted accounting principles. The accounting policies
applied are those set out in AstraZeneca PLC's 2002 Annual Report and Form 20-F.
These interim financial statements do not constitute statutory accounts within
the meaning of Section 240 of the Companies Act 1985. Statutory accounts for
the year ended 31 December 2002 will be filed with the Registrar of Companies
following the Company's Annual General Meeting. The auditor's report on those
accounts was unqualified and did not contain any statement under Section 237 of
the Companies Act 1985.
As part of AstraZeneca's objective to align with best accounting practice, cash
discounts arising from prompt payments of invoices were reclassified from cost
of sales to sales for the year ended 31 December 2002. Comparatives were
reclassified and additional detail at product and territorial level are
available on the AstraZeneca website. Both sales and cost of sales were reduced
by $75m in the first quarter 2002. Neither profits nor net assets were
affected.
2 TERRITORIAL SALES ANALYSIS
% Growth
1st Quarter 1st Quarter
2003 2002 Constant
$m $m Actual Currency
US 2,470 2,383 4 4
Canada 156 129 21 19
North America 2,626 2,512 5 5
France 329 263 25 9
UK 144 178 (19) (27)
Germany 183 164 12 (3)
Italy 208 172 21 5
Sweden 79 64 23 3
Europe others 612 546 12 (2)
Total Europe 1,555 1,387 12 (2)
Japan 243 172 41 32
Rest of World 311 275 13 18
Total 4,735 4,346 9 4
3 PRODUCT SALES ANALYSIS
World US
1st 1st Constant 1st
Quarter Quarter Actual Currency Quarter Actual
2003 2002 Growth Growth 2003 Growth
$m $m % % $m %
Gastrointestinal:
Losec 692 1,192 (42) (45) 287 (60)
Nexium 835 347 141 136 669 135
Others 18 13 38 30 8 100
Total Gastrointestinal 1,545 1,552 - (3) 964 (5)
Cardiovascular:
Zestril 108 277 (61) (64) 20 (89)
Seloken 368 231 59 56 285 76
Atacand 206 149 38 31 102 44
Plendil 110 106 4 (1) 39 (9)
Tenormin 84 94 (11) (14) 13 (41)
Crestor 3 - n/m n/m - -
Others 90 89 1 (9) 4 (33)
Total Cardiovascular 969 946 2 (3) 463 (4)
Respiratory:
Pulmicort 251 227 11 6 133 27
Rhinocort 90 63 43 40 68 58
Symbicort 122 54 126 102 - -
Accolate 31 32 (3) (3) 23 5
Oxis 31 31 - (10) - -
Others 38 35 9 - - -
Total Respiratory 563 442 27 20 224 32
Oncology:
Zoladex 193 187 3 (2) 42 (9)
Casodex 189 123 54 44 60 100
Nolvadex 61 140 (56) (57) 31 (71)
Arimidex 93 65 43 35 33 27
Iressa 19 - n/m n/m - -
Faslodex 22 - n/m n/m 22 n/m
Others 4 5 (20) (20) - -
Total Oncology 581 520 12 6 188 (10)
CNS:
Seroquel 444 329 35 33 360 26
Zomig 108 92 17 13 69 17
Others 8 7 14 14 2 -
Total CNS 560 428 31 28 431 24
Pain, Infection and Other
Pharma:
Diprivan 136 111 23 19 81 53
Merrem 74 67 10 10 13 (13)
Local anaesthetics 101 96 5 (1) 20 (9)
Other Pharma Products 66 68 (3) (13) 17 (6)
Total Pain, Infection and Other
Pharma 377 342 10 5 131 21
Salick Health Care 65 54 20 20 65 20
Astra Tech 44 34 29 8 3 50
Marlow Foods 31 28 11 - 1 -
Total 4,735 4,346 9 4 2,470 4
n/m not meaningful
Shareholder Information
ANNOUNCEMENTS AND MEETINGS
Annual General Meeting 30 April 2003
Announcement of half year results 24 July 2003
Annual Business Review 2 October 2003
Announcement of third quarter and nine month results 23 October 2003
DIVIDENDS
The record date for the second interim dividend payable on 7 April 2003 (in the
UK, Sweden and the US) was 21 February 2003. Ordinary Shares traded ex-dividend
on the London and Stockholm Stock Exchanges from 19 February 2003. ADRs traded
ex-dividend on the New York Stock Exchange from the same date.
Future dividends will normally be paid as follows:
First interim Announced end of July and paid in October.
Second interim Announced in January and paid in April.
TRADEMARKS
The following brand names used in this interim report are trade marks of the
AstraZeneca group of companies:
Accolate Arimidex Astra Tech Atacand Casodex Crestor Diprivan Exanta
Faslodex Iressa Losec Merrem Nexium Nolvadex Oxis Plendil Prilosec
Pulmicort Pulmicort Respules Rhinocort Rhinocort Aqua Seloken Seroquel
Symbicort Tenormin Toprol-XL Zestril Zoladex Zomig
ADDRESSES FOR CORRESPONDENCE
Registrar and Depositary Registered Office Swedish Securities Register
Transfer Office for ADRs Centre
The AstraZeneca Registrar JPMorgan Chase Bank 15 Stanhope Gate VPC AB
Lloyds TSB Registrars ADR Service Center London PO Box 7822
The Causeway PO Box 43013 W1K 1LN S-103 97 Stockholm
Worthing Providence, RI 02940-3013
West Sussex
BN99 6DA
Tel: (0870) 600 3956 Tel: (781) 575 4328 Tel: (020) 7304 5000 Tel: (8) 402 9000
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
In order to utilise the 'Safe Harbor' provisions of the United States Private
Securities Litigation Reform Act of 1995, AstraZeneca is providing the following
cautionary statement. This Interim Report contains forward-looking statements
with respect to the financial condition, results of operations and businesses of
AstraZeneca. By their nature, forward-looking statements and forecasts involve
risk and uncertainty because they relate to events and depend on circumstances
that will occur in the future. There are a number of factors that could cause
actual results and developments to differ materially from that expressed or
implied by these forward-looking statements. These factors include, among other
things, the loss or expiration of patents, marketing exclusivity or trade marks;
exchange rate fluctuations; the risk that R&D will not yield new products that
achieve commercial success; the impact of competition; price controls and price
reductions; taxation risks; the risk of substantial product liability claims;
the impact of any failure by third parties to supply materials or services; the
risk of delay to new product launches; the difficulties of obtaining and
maintaining governmental approvals for products; and the risk of environmental
liabilities.
This information is provided by RNS
The company news service from the London Stock Exchange
END
QRFIIFLTSTIIVIV
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
